Sunday, July 14, 2013

Meeting Report - 8th Hepatitis Pharmacology Workshop

Produced by

Meeting Report - 8th Hepatitis Pharmacology Workshop, Cambridge, USA.

Posted Thursday 11 July 2013

The objective of this workshop was to provide a platform for presentation and discussion of the latest developments in the field, to map all current studies and results, to translate new data to treatment guideline and to educate clinicians on how to best implement current and new drugs.

There were several presentations in Wednesday’s session on drug interactions with new HCV agents in development and one survey on drug interactions with the currently licensed DAAs, boceprevir and telaprevir. The session on Thursday saw presentations on the management of drug interactions in transplant patients and the challenge of treating HIV/HCV coinfected patients.

The meeting report below summarises the presentations relating to drug interactions and pharmacology. The abstract book and slides from the presentations are available to view on line on
the Virology Education website.

Click here for the meeting report (pdf format)

Simeprevir & TMC647055/r
Asunaprevir & Ketoconazole or Rifampicin
Daclatasvir & Midazolam
Daclatasvir and Sofosbuvir
MK ‐ 5172 & Methadone or Buprenorphine
Boceprevir & Telaprevir
BMS ‐ 791325, Daclatasvir & Asunaprevir
Pharmacology of Ledipasvir
Simeprevir & Food

No comments:

Post a Comment